|
|
Profile
|
Delegates :
Hodaka Fujii |
|
Incorporated :
March 1 , 2023 |
Paid in Capital :
6 Million yen |
Employees :
2 人 |
Address :
3-7-14,Waseda,Hirosaki-City,Aomori AOMORI
〒036-8087
|
TEL/FAX :
090-6060-4696 / |
URL：
|
Attachment :
|
Mission/Background :
Wisteriagen was founded by Hodaka Fujii, MD, PhD and Toshitsugu Fujita, PhD to translate their innovative inventions, locus-specific chromatin immunoprecipitation (ChIP) and oligoribonucleotide interference (ORNi)-PCR, into the industrial applications such as exploitation and identification of revolutionary drug targets and detection of rare gene sequences in biological specimens. |
|
Technology & Business
|
1. Locus-specific ChIP
To perform biochemical and molecular biological analyses of specific genomic regions, Wisteriagen developed locus-specific ChIP technologies that comprise insertional ChIP (iChIP) and engineered DNA-binding molecule-mediated ChIP (enChiP) to purify the genomic regions of interest.
Wisteriagen is implementing drug discovery research focusing on specific targets, using the locus-specific ChIP technologies, that regulate gene expression associated with the cause of diseases in oncology and neurology.
2. ORNi-PCR
The ORNi-PCR technology is a method, in which an oligoribonucleotide (ORN, small RNA) to specifically inhibit the amplification of a DNA domain complementary and thus hybridized to the ORN in order to halt a PCR. ORNi-PCR has been reported to have the capacity to distinguish single base mutations with high precision and sensitivity and has thus been used for applications, such as detecting genome-edited cells, DNA methylation analysis, and bacterial flora analysis.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Identification of drug targets for gene expression modulators by using locus-specific ChIP
|
Launched
|
We identify factors regulating abnormal expression of disease-causative genes and screen potential drug targets among them.
|
Acquisition of customers, Alliance
|
Detection of rare gene sequences by using ORNi-PCR
|
Launched
|
We provide technologies to detect rare gene sequences such as mutations in oncogenes in liquid biopsy samples.
|
Acquisition of customers, Alliance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
・Wisteriagen was selected as recipient of grants from Hirosaki city. (July, 2023; July 2024; August, 2024)
|
|
Alliance strategy
|
1. Locus-specific ChIP
・Licensing out of our IPs to pharmaceutical companies
・Collaborative research with pharmaceutical companies
・Contract research with pharmaceutical companies
2. ORNi-PCR
・Licensing out of our IPs to clinical diagnostic companies
|
|
|